<DOC>
	<DOCNO>NCT00623441</DOCNO>
	<brief_summary>The safety efficacy Endeavor ( TM ) ABT-578 Eluting Coronary Stent System assess series study . The stent coat proprietary drug compound design reduce restenosis . This prospective multi-center study initiate : - To document acute mid-term safety overall clinical performance stent system `` real world '' patient population require stent implantation . - To assess event rate patient subgroup specific clinical indication and/or vessel lesion characteristic .</brief_summary>
	<brief_title>E-Five Registry : A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient &gt; 18 year age ( minimum age require local regulation ) The patient consent participate signing `` Patient Informed Consent Form '' and/or authorize collection release medical information sign `` Patient Data Release Consent Form '' . The patient suitable implantation one Endeavor ( TM ) ABT578 Eluting Coronary Stent System one native artery target lesion . Lesion length vessel diameter target lesion ( ) accord `` Indications Use '' mention `` Instructions Use '' come every Endeavor ( TM ) ABT578 Eluting Coronary Stent System . The patient willing able cooperate registry procedure require follow visit . Women known pregnancy lactate . Patients hypersensitivity allergy aspirin , heparin , clopidogrel , ticlopidine , drug ABT578 , rapamycin , tacrolimus , sirolimus similar drug , analogue derivative , cobalt , chromium , nickel , molybdenum contrast medium . Patients antiplatelet and/pr anticoagulation therapy contraindicate . Patients judged lesion prevents complete inflation angioplasty balloon . Current medical condition life expectancy le 12 month . The subject participate another device drug study . Subject must complete followup phase previous study least 30 day prior enrollment trial . The subject may enrol Efive registry . Patients medical condition preclude followup define protocol otherwise limit participation registry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Drug-eluting stent</keyword>
</DOC>